TY - JOUR
T1 - Artificial Intelligence-Based Prediction of Recurrence after Curative Resection for Colorectal Cancer from Digital Pathological Images
AU - Nakanishi, Ryota
AU - Morooka, Ken’ichi
AU - Omori, Kazuki
AU - Toyota, Satoshi
AU - Tanaka, Yasushi
AU - Hasuda, Hirofumi
AU - Koga, Naomichi
AU - Nonaka, Kentaro
AU - Hu, Qingjiang
AU - Nakaji, Yu
AU - Nakanoko, Tomonori
AU - Ando, Koji
AU - Ota, Mitsuhiko
AU - Kimura, Yasue
AU - Oki, Eiji
AU - Oda, Yoshinao
AU - Yoshizumi, Tomoharu
N1 - Publisher Copyright:
© 2022, Society of Surgical Oncology.
PY - 2023/6
Y1 - 2023/6
N2 - Background: To develop an artificial intelligence-based model to predict recurrence after curative resection for stage I–III colorectal cancer from digitized pathological slides. Patients and Methods: In this retrospective study, 471 consecutive patients who underwent curative resection for stage I–III colorectal cancer at our institution from 2004 to 2015 were enrolled, and 512 randomly selected tiles from digitally scanned images of hematoxylin and eosin-stained tumor tissue sections were used to train a convolutional neural network. Five-fold cross-validation was used to validate the model. The association between recurrence and the model’s output scores were analyzed in the test cohorts. Results: The area under the receiver operating characteristic curve of the cross-validation was 0.7245 [95% confidence interval (CI) 0.6707–0.7783; P < 0.0001]. The score successfully classified patients into those with better and worse recurrence free survival (P < 0.0001). Multivariate analysis revealed that a high score was significantly associated with worse recurrence free survival [odds ratio (OR) 1.857; 95% CI 1.248–2.805; P = 0.0021], which was independent from other predictive factors: male sex (P = 0.0238), rectal cancer (P = 0.0396), preoperative abnormal carcinoembryonic antigen (CEA) level (P = 0.0216), pathological T3/T4 stage (P = 0.0162), and pathological positive lymph node metastasis (P < 0.0001). Conclusions: The artificial intelligence-based prediction model discriminated patients with a high risk of recurrence. This approach could help decision-makers consider the benefits of adjuvant chemotherapy.
AB - Background: To develop an artificial intelligence-based model to predict recurrence after curative resection for stage I–III colorectal cancer from digitized pathological slides. Patients and Methods: In this retrospective study, 471 consecutive patients who underwent curative resection for stage I–III colorectal cancer at our institution from 2004 to 2015 were enrolled, and 512 randomly selected tiles from digitally scanned images of hematoxylin and eosin-stained tumor tissue sections were used to train a convolutional neural network. Five-fold cross-validation was used to validate the model. The association between recurrence and the model’s output scores were analyzed in the test cohorts. Results: The area under the receiver operating characteristic curve of the cross-validation was 0.7245 [95% confidence interval (CI) 0.6707–0.7783; P < 0.0001]. The score successfully classified patients into those with better and worse recurrence free survival (P < 0.0001). Multivariate analysis revealed that a high score was significantly associated with worse recurrence free survival [odds ratio (OR) 1.857; 95% CI 1.248–2.805; P = 0.0021], which was independent from other predictive factors: male sex (P = 0.0238), rectal cancer (P = 0.0396), preoperative abnormal carcinoembryonic antigen (CEA) level (P = 0.0216), pathological T3/T4 stage (P = 0.0162), and pathological positive lymph node metastasis (P < 0.0001). Conclusions: The artificial intelligence-based prediction model discriminated patients with a high risk of recurrence. This approach could help decision-makers consider the benefits of adjuvant chemotherapy.
UR - http://www.scopus.com/inward/record.url?scp=85143886312&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85143886312&partnerID=8YFLogxK
U2 - 10.1245/s10434-022-12926-x
DO - 10.1245/s10434-022-12926-x
M3 - Article
C2 - 36512260
AN - SCOPUS:85143886312
SN - 1068-9265
VL - 30
SP - 3506
EP - 3514
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 6
ER -